Share on StockTwits
 

United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,833 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $97.26, for a total transaction of $372,797.58. Following the completion of the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $13,616. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 1.22% during mid-day trading on Thursday, hitting $97.21. 664,458 shares of the company’s stock traded hands. United Therapeutics Corp. has a 1-year low of $52.98 and a 1-year high of $116.65. The stock’s 50-day moving average is $107.3 and its 200-day moving average is $87.66. The company has a market cap of $4.882 billion and a price-to-earnings ratio of 17.45. United Therapeutics Corp. also was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 6,166,867 shares, a drop of 26.3% from the December 31st total of 7,791,595 shares. Approximately 13.4% of the company’s shares are short sold. Based on an average daily volume of 726,990 shares, the days-to-cover ratio is presently 8.5 days.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $91.07.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.